BioStock: Cyxone’s CEO gives a status update

Cyxone recently reached a milestone in its rheumatoid arthritis project, rabeximod, when succeeding in identifying the molecule’s target protein. This means that it is now easier to identify other diseases in which this mechanism of action plays an important role. BioStock reached out to CEO Carl-Magnus Högerkorp for a comment on the company’s year-end report for 2023.

Read the full interview with Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2024/03/cyxones-ceo-gives-a-status-update/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/